Stay up to date on research and information
Sign Up for FORCE NewslettersPolicy Archive
FDA Approves New Direct-to-Consumer Genetic Test for 3 BRCA Mutations
On March 6, 2018, the Food and Drug Administration (FDA) announced approval of a new direct-to-consumer genetic test for three BRCA mutations most commonly found in people with Ashkenazi Jewish (Eastern European) ancestry, often referred to as founder mutations.
With thousands of known BRCA mutations, 23andMe's "Personal Genome Service Genetic Health Risk (GHR) Report for BRCA1/BRCA2 (Selected Variants)" provides consumers with an extremely limited snapshot of potential hereditary cancer risk.
News Briefs
11/18/2024 - Thanked U.S. Reps Ruiz and Bucshon for introducing H.R. 8412, the Clinical Trial Modernization Act, and to express our support for this important legislation.
11/18/2024 - Joined nearly 400 members of the Ad Hoc Group for Medical Research in encouraging House Appropriations Committee leadership to finalize the Labor-HHS spending bill with a $48.9 billion investment in the NIH, in addition to funding for the Advanced Research Projects Agency for Health (ARPA-H).
10/7/2024 - Urged congressional leadership to swiftly pass the SCREENS for Cancer Act, which would reauthorize the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for another five years.